Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations

[1]  M. Filippi,et al.  Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning , 2016, Multiple sclerosis.

[2]  L. Kappos,et al.  BG-12 (dimethyl fumarate) and pregnancy: Preclinical studies and pregnancy outcomes reported during the clinical development program , 2013, Journal of Neurological Sciences.

[3]  A. Sempere,et al.  Switching from natalizumab to fingolimod: an observational study , 2013, Acta neurologica Scandinavica.

[4]  Douglas L Arnold,et al.  Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations , 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[5]  M. Krumbholz,et al.  Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis , 2013, Journal of Neurology.

[6]  F. Barkhof,et al.  PML in a patient treated with dimethyl fumarate from a compounding pharmacy. , 2013, The New England journal of medicine.

[7]  J. Weis,et al.  PML in a patient treated with fumaric acid. , 2013, The New England journal of medicine.

[8]  B Stubinski,et al.  Scoring treatment response in patients with relapsing multiple sclerosis , 2013, Multiple sclerosis.

[9]  G. Tedeschi,et al.  Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice , 2013, Neurological Sciences.

[10]  J. Lechner-Scott,et al.  The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform , 2013, PloS one.

[11]  S. Tomczyk,et al.  Pregnancy Outcomes in Patients Exposed to Intramuscular Interferon beta-1a (IM IFNβ-1a) (S30.006) , 2013 .

[12]  G. Bloomgren,et al.  Evaluation of Pregnancy Outcomes from the TYSABRI® (Natalizumab) Pregnancy Exposure Registry (P02.127) , 2013, Neurology.

[13]  B. Kieseier,et al.  Pregnancy Outcomes from the Teriflunomide Clinical Development Program: Retrospective Analysis of the Teriflunomide Clinical Trial Database (S30.005) , 2013 .

[14]  J. Aarseth,et al.  Stoppers and non‐starters of disease‐modifying treatment in multiple sclerosis , 2013, Acta neurologica Scandinavica.

[15]  Kwiyoung Park,et al.  Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia , 2013, Multiple Sclerosis.

[16]  Christian Confavreux,et al.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.

[17]  Jeffrey A. Cohen,et al.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.

[18]  S. Marousi,et al.  Simultaneous Pml-Iris After Discontinuation of Natalizumab in A Patient With MS , 2012, Neurology.

[19]  M. Calabrese,et al.  Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings , 2012, Multiple sclerosis.

[20]  H. Hartung,et al.  Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod , 2012, Multiple sclerosis.

[21]  C. Pozzilli,et al.  Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study , 2012, BMC Neurology.

[22]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[23]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[24]  F. Cuthbertson,et al.  Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis , 2012, Case reports in medicine.

[25]  A. Synnes,et al.  Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review , 2013, Neurology.

[26]  M. Sahraian,et al.  Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis , 2012, European journal of neurology.

[27]  X. Montalban,et al.  Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response , 2012, European journal of neurology.

[28]  De-kun Li,et al.  A systematic review to calculate background miscarriage rates using life table analysis. , 2012, Birth defects research. Part A, Clinical and molecular teratology.

[29]  A. Green,et al.  Microcystic macular oedema in multiple sclerosis is associated with disease severity. , 2012, Brain : a journal of neurology.

[30]  R. Lenkinski,et al.  Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS , 2012, Neurology.

[31]  R. Hernández-Clares,et al.  Spasticity improvement in patients with relapsing–remitting multiple sclerosis switching from interferon-β to glatiramer acetate: The Escala Study , 2012, Journal of the Neurological Sciences.

[32]  A. Synnes,et al.  Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs , 2012, Multiple sclerosis.

[33]  Ludwig Kappos,et al.  Placebo-controlled trial of oral laquinimod for multiple sclerosis. , 2012, The New England journal of medicine.

[34]  David H. Miller,et al.  Clinically isolated syndromes , 2012, The Lancet Neurology.

[35]  C. Pozzilli,et al.  Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis , 2012, Multiple sclerosis.

[36]  Christian Confavreux,et al.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis. , 2011, The New England journal of medicine.

[37]  E. Leray,et al.  Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients , 2011, Journal of the Neurological Sciences.

[38]  E. Major,et al.  Immune reconstitution inflammatory syndrome in natalizumab-associated PML , 2011, Neurology.

[39]  R. Gold,et al.  A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis , 2011, Journal of the Neurological Sciences.

[40]  A. P. Ross,et al.  Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis , 2011, International journal of clinical practice.

[41]  R. Gold,et al.  Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment , 2011, Multiple sclerosis.

[42]  M. Krumbholz,et al.  De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate , 2011, Journal of Neurology.

[43]  E. Vittinghoff,et al.  Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy , 2011, PloS one.

[44]  G. Moonen,et al.  Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing‐remitting multiple sclerosis , 2011, European journal of neurology.

[45]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[46]  M. Sandberg‐Wollheim,et al.  Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy , 2011, Multiple sclerosis.

[47]  D. Clifford,et al.  Progressive multifocal leukoencephalopathy and other forms of JC virus disease , 2010, Nature Reviews Neurology.

[48]  C. Pozzilli,et al.  Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis , 2010, Neurology.

[49]  M. Boggild,et al.  Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes , 2010, Journal of Neurology.

[50]  L. Airas,et al.  Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland , 2010, Multiple sclerosis.

[51]  M. Mühlau,et al.  The radiologically isolated syndrome: take action when the unexpected is uncovered? , 2010, Journal of Neurology.

[52]  G. Comi,et al.  Freedom from disease activity in multiple sclerosis , 2010, Neurology.

[53]  D. Clifford,et al.  Natalizumab-associated progressive multifocal leukoencephalopathy. , 2012 .

[54]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[55]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[56]  X. Montalban,et al.  Predicting responders to therapies for multiple sclerosis , 2009, Nature Reviews Neurology.

[57]  D. Goodin,et al.  Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode , 2009, Multiple sclerosis.

[58]  D. West,et al.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2009, The Lancet. Oncology.

[59]  B. Källén,et al.  Early pregnancy azathioprine use and pregnancy outcomes. , 2009, Birth defects research. Part A, Clinical and molecular teratology.

[60]  L. Carmona,et al.  Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). , 2009, Clinical and experimental rheumatology.

[61]  C. Polman,et al.  Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis , 2009, The Lancet Neurology.

[62]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. , 2009, Archives of neurology.

[63]  R. Gold,et al.  Interferon beta, birth weight and pregnancy in multiple sclerosis , 2009, Journal of Neurology.

[64]  S. Sorbi,et al.  Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients , 2009, European Neurology.

[65]  X. Montalban,et al.  Oral fingolimod (FTY720) in multiple sclerosis , 2009, Neurology.

[66]  E. Lathi,et al.  A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events , 2009 .

[67]  E. Waubant,et al.  Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis , 2009, Multiple sclerosis.

[68]  A. Ghezzi,et al.  Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients , 2008, Neurological Sciences.

[69]  M. Zappia,et al.  Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? , 2008, Journal of Neurology.

[70]  B. Casanova,et al.  Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon , 2008, Multiple sclerosis.

[71]  A. Carrá,et al.  Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina , 2008, European journal of neurology.

[72]  F. Barkhof,et al.  POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS , 2008, Neurology.

[73]  P. Coyle.  Switching algorithms: from one immunomodulatory agent to another , 2008, Journal of Neurology.

[74]  À. Rovira,et al.  Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients , 2008, Multiple sclerosis.

[75]  A. Coles,et al.  Campath-1H Treatment of Multiple Sclerosis , 2007, Neurodegenerative Diseases.

[76]  G. Filippini,et al.  Azathioprine for multiple sclerosis. , 2007, The Cochrane database of systematic reviews.

[77]  G. Koren,et al.  Pregnancy outcome of women exposed to azathioprine during pregnancy. , 2007, Birth defects research. Part A, Clinical and molecular teratology.

[78]  A. Cavaliere,et al.  The first case of mitoxantrone exposure in early pregnancy. , 2007, Neurotoxicology.

[79]  Serban Constantinescu,et al.  Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or Sirolimus , 2006, Transplantation.

[80]  H. Sørensen,et al.  Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study , 2006, Alimentary pharmacology & therapeutics.

[81]  H. Zwibel.  Glatiramer acetate in treatment‐naïve and prior interferon‐β‐1b‐treated multiple sclerosis patients * , 2006, Acta neurologica Scandinavica.

[82]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[83]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[84]  Daniel J. Bauer,et al.  The reproductive effects of beta interferon therapy in pregnancy , 2005, Neurology.

[85]  Geneva,et al.  Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis , 2005, Neurology.

[86]  L. Magder,et al.  Cyclophosphamide for lupus during pregnancy , 2005, Lupus.

[87]  A. Thompson,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.

[88]  A. Langer-Gould,et al.  Strategies for managing the side effects of treatments for multiple sclerosis , 2004, Neurology.

[89]  D. Goodin,et al.  Randomized, comparative study of interferon β-1a treatment regimens in MS , 2002, Neurology.

[90]  E. Frohman,et al.  Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing Management , 2002, The neurologist.

[91]  J. Haas,et al.  Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy , 2002, Multiple sclerosis.

[92]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[93]  X. Montalban,et al.  Low‐dose steroids reduce flu‐like symptoms at the initiation of IFNP‐1b in relapsing‐remitting MS , 1998, Neurology.

[94]  J. Frank,et al.  Magnetic resonance imaging techniques to monitor short term evolution of multiple sclerosis and to use in preliminary trials. , 1998, Journal of neurology, neurosurgery, and psychiatry.

[95]  G. Comi,et al.  Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-β treatment , 1998, The Italian Journal of Neurological Sciences.

[96]  R. Kinkel,et al.  Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. , 1997, Clinical therapeutics.

[97]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[98]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[99]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[100]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[101]  R. Herndon,et al.  MULTICENTRE DOUBLE-BLIND STUDY OF EFFECT OF INTRATHECALLY ADMINISTERED NATURAL HUMAN FIBROBLAST INTERFERON ON EXACERBATIONS OF MULTIPLE SCLEROSIS☆ , 1986, The Lancet.

[102]  G. Koren,et al.  Cumulative data on pregnancy outcomes after exposure to fingolimod and in comparison with the general population , 2013 .

[103]  S. Constantinescu,et al.  Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. , 2003, Clinical transplants.

[104]  G. Alarcón,et al.  Cyclophosphamide use and pregnancy in lupus. , 2006, Lupus.

[105]  Wheelock Ef,et al.  Participation of Lymphocytes in Viral Infections , 1973 .